Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.
| Published in | Biochemistry and Molecular Biology (Volume 7, Issue 4) |
| DOI | 10.11648/j.bmb.20220704.11 |
| Page(s) | 70-74 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
HIV-1, NRTI Resistance Mutation, Switched to Dolutegravir (DTG) Therapy
| [1] | Myburgh, H., Reynolds, L., Hoddinott, G., van Aswegen, D., Grobbelaar, N., Gunst, C., Jennings, K., Kruger, J., Louis, F., Mubekapi-Musadaidzwa, C., Viljoen, L., Wademan, D., & Bock, P. (2021). Implementing 'universal' access to antiretroviral treatment in South Africa: a scoping review on research priorities. Health Policy Plan, 36 (6), 923-938. doi: 10.1093/heapol/czaa094. |
| [2] | De Clercq, J., Rutsaert, S., De Scheerder, M.-A., Verhofstede, C., Callens, S., & Vandekerckhove, L. (2020). Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clinica Belgica, 77 (1), 168-176. doi: 10.1080/17843286.2020.1770413. |
| [3] | Ministry of Health and Public Hygiene (MSHP). The “Test and Treat All” approach in the context of the Care and Support of PLHIV in Côte d’Ivoire. Circular Note N°0001/MSHP/DGS/PNLS/DC of 07 February 2017 for the attention of Health Providers. |
| [4] | World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1; 2019 |
| [5] | Mbhele, N., Chimukangara, B., & Gordon, M. (2021). HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents, 57 (5), 106343. doi: 10.1016/j.ijantimicag.2021.106343. |
| [6] | Laskey, S. B. & Siliciano, R. F. (2016). Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight, 1 (19): e90033. doi: 10.1172/jci.insight.90033. |
| [7] | Pham, H., T., Mesplède, T., & Wainberg, M., A. (2016). Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology, 13 (1), 31. doi: 10.1186/s12977-016-0265-x. |
| [8] | Malet, I., Thierry, E., Wirden, M., Lebourgeois, S., Subra, F., Katlama, C., Deprez, E., Calvez, V., Marcelin, A., G., & Delelis, O. (2015). Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother, 70 (10), 2870-80. doi: 10.1093/jac/dkv197. |
| [9] | Ndashimye, E., & Arts, E. J. (2021). Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings. International Journal of Infectious Diseases, 105, 298–303. doi: 10.1016/j.ijid.2021.03.018. |
| [10] | Blanco, J. L., Rojas, J., Paredes, R., Negredo, E., Mallolas, J., Casadella, M., Clotet, B., Gatell, J. M., de Lazzari, E., Martinez, E., & DOLAM Study Team (2018). Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. The Journal of antimicrobial chemotherapy, 73 (7), 1965–1971. https://doi.org/10.1093/jac/dky093. |
| [11] | Hocqueloux, L., Raffi, F., Prazuck, T., Bernard, L., Sunder, S., Esnault, J. L., Rey, D., Le Moal, G., Roncato-Saberan, M., André, M., Billaud, E., Valéry, A., Avettand-Fènoël, V., Parienti, J. J., Allavena, C., & MONCAY study group (2019). Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 69 (9), 1498–1505. https://doi.org/10.1093/cid/ciy1132 |
| [12] | Nagami, E. H., Thakarar, K., & Sax PE. (2021). Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance. Open Forum Infectious Diseases, 9 (2), ofab648. doi: 10.1093/ofid/ofab648. |
| [13] | Wijting, I., Rokx, C., Boucher, C., van Kampen, J., Pas, S., de Vries-Sluijs, T., Schurink, C., Bax, H., Derksen, M., Andrinopoulou, E. R., van der Ende, M., van Gorp, E., Nouwen, J., Verbon, A., Bierman, W., & Rijnders, B. (2017). Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. The lancet. HIV, 4 (12), e547–e554. https://doi.org/10.1016/S2352-3018(17)30152-2 |
APA Style
Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. (2022). Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology, 7(4), 70-74. https://doi.org/10.11648/j.bmb.20220704.11
ACS Style
Dechi Jean-Jacques Renaud; Toni Thomas D'Aquin; Cisse-Camara Massara; N'din Jean-Louis Philippe; Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem. Mol. Biol. 2022, 7(4), 70-74. doi: 10.11648/j.bmb.20220704.11
AMA Style
Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem Mol Biol. 2022;7(4):70-74. doi: 10.11648/j.bmb.20220704.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bmb.20220704.11,
author = {Dechi Jean-Jacques Renaud and Toni Thomas D'Aquin and Cisse-Camara Massara and N'din Jean-Louis Philippe and Ake Aya Jeanne Armande and Siransy Kouabla Liliane and Sekongo Yassongui Mamadou and Gogbe Leto Olivier and Brou Emmanuel and Fieni Flore and Wawa Amedee Junior and Aby Roland and Kouakou Kouadio and Chenal Henri},
title = {Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination},
journal = {Biochemistry and Molecular Biology},
volume = {7},
number = {4},
pages = {70-74},
doi = {10.11648/j.bmb.20220704.11},
url = {https://doi.org/10.11648/j.bmb.20220704.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20220704.11},
abstract = {Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.},
year = {2022}
}
TY - JOUR T1 - Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination AU - Dechi Jean-Jacques Renaud AU - Toni Thomas D'Aquin AU - Cisse-Camara Massara AU - N'din Jean-Louis Philippe AU - Ake Aya Jeanne Armande AU - Siransy Kouabla Liliane AU - Sekongo Yassongui Mamadou AU - Gogbe Leto Olivier AU - Brou Emmanuel AU - Fieni Flore AU - Wawa Amedee Junior AU - Aby Roland AU - Kouakou Kouadio AU - Chenal Henri Y1 - 2022/10/17 PY - 2022 N1 - https://doi.org/10.11648/j.bmb.20220704.11 DO - 10.11648/j.bmb.20220704.11 T2 - Biochemistry and Molecular Biology JF - Biochemistry and Molecular Biology JO - Biochemistry and Molecular Biology SP - 70 EP - 74 PB - Science Publishing Group SN - 2575-5048 UR - https://doi.org/10.11648/j.bmb.20220704.11 AB - Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing. VL - 7 IS - 4 ER -
Information
Email: